{"id":768901,"date":"2023-07-11T10:10:23","date_gmt":"2023-07-11T14:10:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/"},"modified":"2023-07-11T10:10:23","modified_gmt":"2023-07-11T14:10:23","slug":"longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/","title":{"rendered":"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer"},"content":{"rendered":"

\nExperienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs
\n<\/h2>\n
\n

MIAMI, July 11, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Nataliya Agafonova, M. D., as the Company\u2019s Chief Medical Officer (CMO), effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron\u2019s global clinical development and regulatory strategy for the Company\u2019s investigational products.<\/p>\n

\u201cDr. Agafonova brings deep pharmaceutical industry experience and an extensive background in successful drug development, and we are delighted to welcome her to the Longeveron leadership team,\u201d said Wa\u2019el Hashad, Chief Executive Officer of Longeveron. \u201cWe look forward to working with her to advance our Lomecel-B\u2122 regenerative medical therapy from proof-of-concept, hopefully through regulatory approval and commercialization.\u201d<\/p>\n

\u201cI am very excited about the pioneering work in cellular therapies being done by Longeveron, and about the potential of our lead asset Lomecel-B\u2122 in indications such as hypoplastic left heart syndrome,\u201d said Dr. Agafonova. \u201cThis Company has scientific and operational excellence at its foundational core, and am delighted to join Wa\u2019el and my leadership colleagues to realize the full potential of these assets.\u201d<\/p>\n

Dr. Agafonova joins Longeveron from Otsuka Pharmaceutical, where she served as Clinical Development Lead, Senior Medical Director, and Product Development Chair. Previously, she was the Clinical Development Lead and Senior Medical Director at Bristol-Myers Squibb. Dr. Agafonova previously held several senior leadership positions in clinical development and pharmacovigilance at Ardea Bioscience, Biogen, Amgen, and Genzyme corporation. Dr. Agafonova has extensive experience in therapeutic areas such as autoimmune, hematology, neuroscience, and oncology. Her cross-therapeutic expertise in drug development helped to bring several products to the U.S. and EU market. Prior to her industry experience, Dr. Agafonova served as a physician at Ukrainian Research Institute of Oncology and Radiology. Dr. Agafonova earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.<\/p>\n

\n About Longeveron Inc.<\/strong>
\n
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s lead investigational product is Lomecel-B\u2122 an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B\u2122 has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B\u2122 through clinical trials in three indications: hypoplastic left heart syndrome (HLHS), Alzheimer\u2019s Disease, and Aging-Related Frailty. Additional information about the Company is available at www.longeveron.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements about the ability of Longeveron\u2019s clinical trials to demonstrate safety and efficacy of the Company\u2019s product candidates, and other positive results; the timing and focus of the Company\u2019s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company\u2019s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company\u2019s product candidates; the Company\u2019s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company\u2019s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company\u2019s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company\u2019s ability to attract and retain such personnel; the Company\u2019s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company\u2019s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company\u2019s financial performance, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron\u2019s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 14, 2023. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.<\/p>\n

\n
\n Investor Contact<\/u>
\n <\/strong>
\n
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: <\/strong>mmoyer@lifesciadvisors.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs MIAMI, July 11, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Nataliya Agafonova, M. D., as the Company\u2019s Chief Medical Officer (CMO), effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron\u2019s global clinical development and regulatory strategy for the Company\u2019s investigational products. \u201cDr. Agafonova brings deep pharmaceutical industry experience and an extensive background in successful drug development, and we are delighted to welcome her to the Longeveron leadership team,\u201d said Wa\u2019el Hashad, Chief Executive Officer of Longeveron. \u201cWe look forward to … <\/p>\n

Continue reading “Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768901","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLongeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs MIAMI, July 11, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Nataliya Agafonova, M. D., as the Company\u2019s Chief Medical Officer (CMO), effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron\u2019s global clinical development and regulatory strategy for the Company\u2019s investigational products. \u201cDr. Agafonova brings deep pharmaceutical industry experience and an extensive background in successful drug development, and we are delighted to welcome her to the Longeveron leadership team,\u201d said Wa\u2019el Hashad, Chief Executive Officer of Longeveron. \u201cWe look forward to … Continue reading "Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-11T14:10:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer\",\"datePublished\":\"2023-07-11T14:10:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/\"},\"wordCount\":970,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/\",\"name\":\"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=\",\"datePublished\":\"2023-07-11T14:10:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer - Market Newsdesk","og_description":"Experienced Pharma Industry Clinical Operations Leader to Spearhead Development of Cellular Therapy Programs MIAMI, July 11, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the appointment of Nataliya Agafonova, M. D., as the Company\u2019s Chief Medical Officer (CMO), effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron\u2019s global clinical development and regulatory strategy for the Company\u2019s investigational products. \u201cDr. Agafonova brings deep pharmaceutical industry experience and an extensive background in successful drug development, and we are delighted to welcome her to the Longeveron leadership team,\u201d said Wa\u2019el Hashad, Chief Executive Officer of Longeveron. \u201cWe look forward to … Continue reading \"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-11T14:10:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer","datePublished":"2023-07-11T14:10:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/"},"wordCount":970,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/","name":"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=","datePublished":"2023-07-11T14:10:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjE1MSM1Njg1MTM4IzIyMDcwNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/longeveron-appoints-dr-nataliya-agafonova-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768901","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768901"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768901\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768901"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768901"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768901"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}